Trial Profile
A Single-Dose Pharmacokinetic Study of Abemaciclib (LY2835219) in Subjects With Varying Degrees of Hepatic Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary)
- Indications Breast cancer; Mantle-cell lymphoma; Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 16 Nov 2018 Results developed mechanistic population pharmacokinetics model to estimate changes in drug extraction and CYP3A4-mediated biotransformation, presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
- 11 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 31 Mar 2015 New trial record